SINOVAC Biotech's Albumin-Bound Paclitaxel (Apexelsin®) Gains Marketing Approvals in Macao and Malaysia, Secures GMP Certification in Turkey

Every day AI Express, according toKexing BiopharmNews: Recently, Apexelsin®, the important anti-tumor product (paclitaxel for injection, albumin-bound) developed in collaboration with Haichang Biotech, has been granted marketing authorization in Macao, China, and Malaysia. Additionally, the production line of this product has successfully obtained the GMP certificate from the Turkish Medicines and Medical Devices Agency (TITCK). Apexelsin® has achieved several key milestones in its global market access strategy, further expanding its sales regions.